Investigational drug · Phase 2
VO659
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Spinocerebellar Ataxia Type 1, Spinocerebellar Ataxia Type 3, Huntington Disease.
Phase 2Last checked: Nov 19, 2026Latest source record: Aug 19, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "VO659"
First trial start
2023
Feb 14, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "VO659", any sponsor or status.
Conditions studied
As listed on its trial records.
- Spinocerebellar Ataxia Type 1
- Spinocerebellar Ataxia Type 3
- Huntington Disease
Approved drugs for the same conditions: Huntington's disease chorea · Neurology
Largest trials
Live from ClinicalTrials.gov: studies naming "VO659" as an intervention, largest first.
Vico Therapeutics B. V.Industry
NCT05822908 · 68 participants (planned) · Start Feb 14, 2023 · Primary completion Apr 1, 2028
Drug: VO659 · For: Spinocerebellar Ataxia Type 1; Spinocerebellar Ataxia Type 3; Huntington Disease
Sites: Copenhagen, Denmark; Angers, France; Montpellier, France · 14 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Spinocerebellar Ataxia Type 1
- UC-MSCRY_SW01 cell, Human umbilical cord mesenchymal stem cellsPhase 28 trials
Jiangsu Renocell Biotech Company · Acute Respiratory Distress Syndrome, Lupus Nephritis, Spinocerebellar Ataxia Type 1
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.